NewcelX Raises $1.55M at 20% Premium to Market, Led by Healthcare Investors
NCEL sits 28% above its 52-week low of $1.83.
Summary
NewcelX is selling 471,125 common shares at $3.29 each — a 20% premium to the November 6 close — plus 353,344 warrants struck at $3.75, for gross proceeds of about $1.55 million. The premium pricing is unusual for a micro-cap that disclosed a going concern warning in its September 6-K, with cash down to $710K and a $2.9M first-half loss; investors paid up rather than demanding a discount. The raise is small relative to the company's needs, so the $25 million equity line and the pending sale of the legacy Mazindol portfolio to REA Holdings remain the bigger funding levers. Proceeds go to the FDA-required IND-enabling toxicology study for NCEL-101, cell manufacturing work, and preparation for a Phase 1/2a trial in 2027 with Eledon Pharmaceuticals. The placement is expected to close on or about November 23, 2026, subject to customary conditions.
At the time of this announcement, NCEL was trading at $2.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7M. The 52-week trading range was $1.83 to $5.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.